Welcome to our dedicated page for Enovis SEC filings (Ticker: ENOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Enovis Corporation (NYSE: ENOV) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Enovis describes itself as an innovation-driven medical technology growth company with two primary segments, Prevention & Recovery (P&R) and Reconstructive (Recon), and its filings offer detailed insight into how this orthopedic-focused business reports its financial condition, capital structure and governance matters.
Investors can review Form 8-K filings where Enovis reports material events, such as quarterly earnings releases, changes in senior leadership roles, amendments to its credit agreement and other significant corporate developments. For example, recent 8-Ks have covered second- and third-quarter financial results, a retirement transition for a senior human resources executive, and an amendment to the company’s credit agreement that adjusts maturity dates, leverage ratio thresholds and borrowing terms.
Beyond current reports, Enovis’ annual reports on Form 10-K and quarterly reports on Form 10-Q (accessible via EDGAR) typically contain segment information for Prevention & Recovery and Reconstructive, discussions of non-GAAP measures such as adjusted EBITDA and adjusted net income, and risk factor disclosures that may reference acquisitions and integration, including the acquisition of Lima. These filings help explain how the company evaluates its performance and manages its medical technology portfolio.
Stock Titan enhances access to Enovis filings by pairing real-time updates from EDGAR with AI-powered summaries that explain the key points in plain language. Users can quickly understand what a new 8-K, 10-Q or 10-K means for Enovis’ operations, capital structure or governance without reading every page. The platform also makes it easier to track items such as credit agreement amendments and other direct financial obligations that Enovis reports under the SEC’s requirements.
Enovis Corp reported an insider stock purchase by a company officer. On 11/25/2025, the officer bought 2,468 shares of Enovis common stock at a price of $30.32 per share in an open-market transaction coded as a purchase. Following this trade, the officer directly owns 12,302 shares of Enovis common stock. The filing was made on Form 4 for one reporting person and signed by attorney-in-fact Brian P. Hanigan.
Enovis (ENOV) reported Q3 2025 results with net sales of $548.9 million, up from $505.2 million a year ago, but recorded a non-cash goodwill impairment of $548.4 million. The charge drove an operating loss of $558.5 million and a net loss of $570.9 million, or $9.99 per share from continuing operations.
Both segments grew: Prevention & Recovery sales were $290.9 million and Reconstructive sales were $258.0 million. Adjusted EBITDA was $94.8 million versus $90.2 million, reflecting underlying operating performance despite elevated non-cash items.
The company approved and closed the sale of its Dr Comfort Footcare Solutions line to Promus Equity Partners for up to $60 million in cash, including $45 million upfront and up to $15 million contingent on milestones. Enovis recognized a $7.6 million loss on assets held for sale in connection with the transaction. Year-to-date, cash from operations was $128.7 million. Total debt was $1.36 billion, with $355 million available on the Revolver and a 5.75% weighted-average borrowing rate. Shares outstanding were 57.19 million as of October 31, 2025.
Enovis Corporation filed an 8-K announcing it issued a press release with financial results for the third quarter ended October 3, 2025.
The company scheduled a conference call for 8:30 a.m. Eastern on November 6, 2025 to discuss these results. The press release is included as Exhibit 99.1.
Enovis director Angela S. Lalor reported acquiring 742 shares of Enovis Corp (ENOV) on 09/30/2025 at a reported price of $0.00, increasing her direct beneficial ownership to 21,295 shares. The Form 4 shows the filing was signed by attorney-in-fact Brian P. Hanigan on 10/01/2025. The filing identifies Lalor as a director and indicates this is a single-person Form 4 filing. No derivative transactions or additional details are reported.
Damien McDonald, listed as Chief Executive Officer and Director of Enovis Corporation (ENOV), purchased 6,457 shares of Enovis common stock on 09/11/2025. The reported weighted-average price per share was $30.97, with transaction prices ranging from $30.73 to $31.16. After the purchase, the reporting person beneficially owned 102,753 shares. The Form 4 was signed on behalf of Mr. McDonald by attorney-in-fact Brian P. Hanigan.
Insider purchase by Enovis executive: Tandy Bradley J, SVP and Chief Legal Officer of Enovis Corporation (ENOV), reported purchasing 3,200 shares of Enovis common stock on 08/22/2025 at a price of $31.41 per share. After the transaction, Mr. Bradley beneficially owned 43,515 shares. The Form 4 was signed via attorney-in-fact on 08/25/2025.
Enovis insider purchase disclosed on Form 4. Philip Benjamin Berry, SVP and Chief Financial Officer, purchased 2,500 shares of Enovis Corporation (ticker ENOV) on 08/20/2025 at a price of $29.71 per share. After the transaction, Mr. Berry beneficially owned 116,729 shares. The Form 4 was filed as a single reporting person filing and was signed by attorney-in-fact Brian P. Hanigan on 08/20/2025.
The filing discloses that multiple American Century entities and the Stowers Institute report material beneficial ownership in Enovis Corporation common stock. American Century Investment Management, Inc., American Century Companies, Inc. and Stowers Institute each report beneficial ownership of 4,737,327 shares, representing 8.3% of the class, with sole voting power of 4,580,116 shares and sole dispositive power of 4,737,327 shares as shown on their cover pages. American Century Capital Portfolios, Inc. reports ownership of 3,060,000 shares, representing 5.4% of the class, with sole voting and dispositive power.
The filing states these securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer. An exhibit shows that the reporting persons consented to a joint filing, and signatures certify the accuracy of the statement.
Davenport & Co LLC reported beneficial ownership of 2,756,270 shares of Enovis common stock, representing 4.83% of the class. The filer discloses sole voting power over 2,730,225 shares and sole dispositive power over 2,756,145 shares. The statement is filed on Schedule 13G as an investment adviser and indicates the holding is 5% or less of the class.
This filing also contains a certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Enovis Corp. (ENOV) – Form 4 filing dated 08/07/2025
Group President, Recon, Louis Vogt reported one transaction on 08/05/2025. The Form 4 shows an F-code entry—shares withheld by the company to cover tax obligations arising from the net settlement of previously granted restricted stock units.
- Securities withheld: 460 common shares
- Price applied for withholding: $26.46 per share
- Post-transaction direct holdings: 36,385 common shares